Last 12 months
Inside the activity.
0 purchase rows · 20 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 7 |
| Mar 2026 | 0 | 3 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 2 |
| Aug 2026 | 0 | 5 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 01, 2026 Filed Sep 3, 2026 12:21 UTC |
Oyegunwa AkinboladeEVP, CIO & CTO
|
GrantRestricted Stock Unit · Derivative | 750 | $0.00 | $0.00 |
DisclosureSEC source: 0000920148-26-000193 · form4.xml · derivative · entry 1 Oyegunwa Akinbolade · CIK 0002042869 · EVP, CIO & CTO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,940 Underlying: Common Stock · 750 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on September 1, 2027. F2 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on September 1, 2027. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 12:19 UTC |
Meltzer Jonathan CEVP, COO
|
GrantRestricted Stock Unit · Derivative | 900 | $0.00 | $0.00 |
DisclosureSEC source: 0000920148-26-000192 · form4.xml · derivative · entry 1 Meltzer Jonathan C · CIK 0002103998 · EVP, COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,594 Underlying: Common Stock · 900 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on September 1, 2027. F2 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on September 1, 2027. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 12:18 UTC |
Vaughn Bryan TEVP and President, Diagnostics
|
GrantRestricted Stock Unit · Derivative | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000920148-26-000191 · form4.xml · derivative · entry 1 Vaughn Bryan T · CIK 0002103999 · EVP and President, Diagnostics 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,204 Underlying: Common Stock · 1,500 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on September 1, 2027. F2 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on September 1, 2027. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 12:07 UTC |
Caveney Brian JEVP, Pres of BLS, CMO & CSO
|
GrantRestricted Stock Unit · Derivative | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000920148-26-000190 · form4.xml · derivative · entry 1 Caveney Brian J · CIK 0001717915 · EVP, Pres of BLS, CMO & CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,170 Underlying: Common Stock · 3,000 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on September 1, 2027. F2 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on September 1, 2027. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| August 17, 2026 Filed Aug 18, 2026 12:10 UTC |
ANDERSON KERRII BDirector
|
SaleCommon Stock | 3,000 | $318.02 | $954,060.00 |
DisclosureSEC source: 0000920148-26-000186 · form4.xml · nonDerivative · entry 1 ANDERSON KERRII B · CIK 0001227159 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,563 F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| August 11, 2026 Filed Aug 12, 2026 18:31 UTC |
Schechter Adam HDirector · President & CEO
|
SaleCommon Stock | 4,669 | $320.37 | $1,495,807.53 |
DisclosureSEC source: 0000920148-26-000177 · form4.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 102,565 F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| August 04, 2026 Filed Aug 6, 2026 12:26 UTC |
Summy Amy B.EVP, Chief Marketing Officer
|
SaleCommon Stock | 924 | $306.74 | $283,427.76 |
DisclosureSEC source: 0000920148-26-000176 · form4.xml · nonDerivative · entry 1 Summy Amy B. · CIK 0001805303 · EVP, Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,955.5 Read SEC document |
| August 03, 2026 Filed Aug 5, 2026 15:17 UTC |
Wilkinson Peter JSVP, Chief Accounting Officer
|
Exercise / conversionNon-qualified Stock Options · Derivative | 1,338 | $0.00 Strike: $209.25 | $0.00 |
DisclosureSEC source: 0000920148-26-000172 · form4.xml · derivative · entry 4 Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,338 shares Expires 2031-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option (right to buy) granted pursuant to the Labcorp Holdings Inc. Amended and Restated 2016 Omnibus Incentive Plan. F2 · shares: Represents amounts automatically adjusted based on the final adjustment ratio applied to equity awards in connection with the spin-off of Fortrea Holdings Inc. ("Fortrea") by Labcorp Holdings Inc. ("Labcorp"), calculated pursuant to the terms of the Employee Matters Agreement by and between Labcorp and Fortrea. F3 · derivative.exercise_date: The options vested in three equal annual installments beginning on the date reflected in this column and are now fully exercisable. Read SEC document |
| August 03, 2026 Filed Aug 5, 2026 15:17 UTC |
Wilkinson Peter JSVP, Chief Accounting Officer
|
SaleCommon Stock | 1,338 | $309.23 | $413,751.21 |
DisclosureSEC source: 0000920148-26-000172 · form4.xml · nonDerivative · entry 3 Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,770.2194 Read SEC document |
| August 03, 2026 Filed Aug 5, 2026 15:17 UTC |
Wilkinson Peter JSVP, Chief Accounting Officer
|
Exercise / conversionCommon Stock | 1,338 | $209.25 | $279,976.50 |
DisclosureSEC source: 0000920148-26-000172 · form4.xml · nonDerivative · entry 2 Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,108.2194 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 03, 2026 Filed Aug 5, 2026 15:17 UTC |
Wilkinson Peter JSVP, Chief Accounting Officer
|
SaleCommon Stock | 82 | $309.22 | $25,356.04 |
DisclosureSEC source: 0000920148-26-000172 · form4.xml · nonDerivative · entry 1 Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,770.2194 Read SEC document |
| July 02, 2026 Filed Jul 6, 2026 13:37 UTC |
Kyle Kathryn WEVP, Chief Legal Officer
|
SaleCommon Stock | 92 | $286.19 | $26,329.48 |
DisclosureSEC source: 0000920148-26-000152 · form4.xml · nonDerivative · entry 3 Kyle Kathryn W · CIK 0002103996 · EVP, Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,904.4574 F3 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| July 02, 2026 Filed Jul 6, 2026 13:36 UTC |
Vaughn Bryan TEVP and President, Diagnostics
|
SaleCommon Stock | 234 | $286.19 | $66,968.46 |
DisclosureSEC source: 0000920148-26-000151 · form4.xml · nonDerivative · entry 3 Vaughn Bryan T · CIK 0002103999 · EVP and President, Diagnostics 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,745.5702 F3 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 13:37 UTC |
Kyle Kathryn WEVP, Chief Legal Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 256 | $0.00 | $0.00 |
DisclosureSEC source: 0000920148-26-000152 · form4.xml · derivative · entry 4 Kyle Kathryn W · CIK 0002103996 · EVP, Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,008 Underlying: Common Stock · 256 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. F4 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on July 1, 2026. F4 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on July 1, 2026. F5 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 13:37 UTC |
Kyle Kathryn WEVP, Chief Legal Officer
|
Tax withholdingCommon Stock | 73 | $283.88 | $20,723.24 |
DisclosureSEC source: 0000920148-26-000152 · form4.xml · nonDerivative · entry 2 Kyle Kathryn W · CIK 0002103996 · EVP, Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,996.4574 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 13:37 UTC |
Kyle Kathryn WEVP, Chief Legal Officer
|
Exercise / conversionCommon Stock | 256 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000920148-26-000152 · form4.xml · nonDerivative · entry 1 Kyle Kathryn W · CIK 0002103996 · EVP, Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,069.4574 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 13:36 UTC |
Vaughn Bryan TEVP and President, Diagnostics
|
Exercise / conversionRestricted Stock Unit · Derivative | 327 | $0.00 | $0.00 |
DisclosureSEC source: 0000920148-26-000151 · form4.xml · derivative · entry 4 Vaughn Bryan T · CIK 0002103999 · EVP and President, Diagnostics 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,704 Underlying: Common Stock · 327 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. F4 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on July 1, 2026. F4 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on July 1, 2026. F5 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 13:36 UTC |
Vaughn Bryan TEVP and President, Diagnostics
|
Tax withholdingCommon Stock | 93 | $283.88 | $26,400.84 |
DisclosureSEC source: 0000920148-26-000151 · form4.xml · nonDerivative · entry 2 Vaughn Bryan T · CIK 0002103999 · EVP and President, Diagnostics 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,979.5702 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 13:36 UTC |
Vaughn Bryan TEVP and President, Diagnostics
|
Exercise / conversionCommon Stock | 327 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000920148-26-000151 · form4.xml · nonDerivative · entry 1 Vaughn Bryan T · CIK 0002103999 · EVP and President, Diagnostics 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,072.5702 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. Read SEC document |
| June 08, 2026 Filed Jun 10, 2026 13:01 UTC |
Kyle Kathryn WEVP, Chief Legal Officer
|
SaleCommon Stock | 762 | $263.89 | $201,084.18 |
DisclosureSEC source: 0000920148-26-000148 · form4.xml · nonDerivative · entry 1 Kyle Kathryn W · CIK 0002103996 · EVP, Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,813.4574 F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| May 11, 2026 Filed May 13, 2026 13:30 UTC |
Schechter Adam HDirector · President & CEO
|
SaleCommon Stock | 5,903 | $254.50 | $1,502,313.50 |
DisclosureSEC source: 0000920148-26-000140 · form4.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 107,234 F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| March 27, 2026 Filed Mar 30, 2026 16:54 UTC |
Wilkinson Peter JSVP, Chief Accounting Officer
|
SaleCommon Stock | 1,633 | $267.05 | $436,092.65 |
DisclosureSEC source: 0000920148-26-000122 · form4.xml · nonDerivative · entry 3 Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,852.2194 F3 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| March 27, 2026 Filed Mar 30, 2026 16:44 UTC |
Meltzer Jonathan CEVP, Operations
|
SaleCommon Stock | 839 | $267.05 | $224,054.95 |
DisclosureSEC source: 0000920148-26-000117 · form4.xml · nonDerivative · entry 3 Meltzer Jonathan C · CIK 0002103998 · EVP, Operations 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,620.3256 F3 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| March 26, 2026 Filed Mar 30, 2026 16:56 UTC |
Schroeder Mark SEVP, Pres Diagnostics & COO
|
Tax withholdingCommon Stock | 1,468 | $268.38 | $393,981.84 |
DisclosureSEC source: 0000920148-26-000124 · form4.xml · nonDerivative · entry 4 Schroeder Mark S · CIK 0001793112 · EVP, Pres Diagnostics & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,677.1426 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| March 26, 2026 Filed Mar 30, 2026 16:56 UTC |
Schroeder Mark SEVP, Pres Diagnostics & COO
|
GrantCommon Stock | 2,968 | $0.00 | $0.00 |
DisclosureSEC source: 0000920148-26-000124 · form4.xml · nonDerivative · entry 3 Schroeder Mark S · CIK 0001793112 · EVP, Pres Diagnostics & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,145.1426 F3 · kind: Shares acquired on March 26, 2026, pursuant to a performance award granted on May 5, 2023, relating to performance during the three-year period ended December 31, 2025. Read SEC document |
| March 26, 2026 Filed Mar 30, 2026 16:56 UTC |
Schroeder Mark SEVP, Pres Diagnostics & COO
|
Tax withholdingCommon Stock | 4,600 | $268.38 | $1,234,548.00 |
DisclosureSEC source: 0000920148-26-000124 · form4.xml · nonDerivative · entry 2 Schroeder Mark S · CIK 0001793112 · EVP, Pres Diagnostics & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,177.1426 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| March 26, 2026 Filed Mar 30, 2026 16:56 UTC |
Schroeder Mark SEVP, Pres Diagnostics & COO
|
GrantCommon Stock | 9,304 | $0.00 | $0.00 |
DisclosureSEC source: 0000920148-26-000124 · form4.xml · nonDerivative · entry 1 Schroeder Mark S · CIK 0001793112 · EVP, Pres Diagnostics & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,777.1426 F1 · kind: Shares acquired on March 26, 2026, pursuant to a performance award granted on February 7, 2023, relating to performance during the three-year period ended December 31, 2025. Read SEC document |
| March 26, 2026 Filed Mar 30, 2026 16:58 UTC |
Schechter Adam HDirector · President & CEO
|
Tax withholdingCommon Stock | 26,106 | $268.38 | $7,006,328.28 |
DisclosureSEC source: 0000920148-26-000126 · form4.xml · nonDerivative · entry 2 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,137 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| March 26, 2026 Filed Mar 30, 2026 16:58 UTC |
Schechter Adam HDirector · President & CEO
|
GrantCommon Stock | 58,470 | $0.00 | $0.00 |
DisclosureSEC source: 0000920148-26-000126 · form4.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 139,243 F1 · kind: Shares acquired on March 26, 2026, pursuant to a performance award granted on February 7, 2023, relating to performance during the three-year period ended December 31, 2025. Read SEC document |
| March 26, 2026 Filed Mar 30, 2026 16:57 UTC |
GRAHAM ANITA ZEVP, CHRO
|
Tax withholdingCommon Stock | 2,879 | $268.38 | $772,666.02 |
DisclosureSEC source: 0000920148-26-000125 · form4.xml · nonDerivative · entry 2 GRAHAM ANITA Z · CIK 0001206814 · EVP, CHRO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,185 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| March 26, 2026 Filed Mar 30, 2026 16:57 UTC |
GRAHAM ANITA ZEVP, CHRO
|
GrantCommon Stock | 6,604 | $0.00 | $0.00 |
DisclosureSEC source: 0000920148-26-000125 · form4.xml · nonDerivative · entry 1 GRAHAM ANITA Z · CIK 0001206814 · EVP, CHRO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,064 F1 · kind: Shares acquired on March 26, 2026, pursuant to a performance award granted on April 5, 2023, relating to performance during the three-year period ended December 31, 2025. Read SEC document |
| March 26, 2026 Filed Mar 30, 2026 16:55 UTC |
Caveney Brian JEVP, Pres of ED, CMO & CSO
|
Tax withholdingCommon Stock | 863 | $268.38 | $231,611.94 |
DisclosureSEC source: 0000920148-26-000123 · form4.xml · nonDerivative · entry 4 Caveney Brian J · CIK 0001717915 · EVP, Pres of ED, CMO & CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,491.9234 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| March 26, 2026 Filed Mar 30, 2026 16:55 UTC |
Caveney Brian JEVP, Pres of ED, CMO & CSO
|
GrantCommon Stock | 1,986 | $0.00 | $0.00 |
DisclosureSEC source: 0000920148-26-000123 · form4.xml · nonDerivative · entry 3 Caveney Brian J · CIK 0001717915 · EVP, Pres of ED, CMO & CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,354.9234 F3 · kind: Shares acquired on March 26, 2026, pursuant to a performance award granted on May 5, 2023, relating to performance during the three-year period ended December 31, 2025. Read SEC document |
| March 26, 2026 Filed Mar 30, 2026 16:55 UTC |
Caveney Brian JEVP, Pres of ED, CMO & CSO
|
Tax withholdingCommon Stock | 4,042 | $268.38 | $1,084,791.96 |
DisclosureSEC source: 0000920148-26-000123 · form4.xml · nonDerivative · entry 2 Caveney Brian J · CIK 0001717915 · EVP, Pres of ED, CMO & CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,368.9234 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| March 26, 2026 Filed Mar 30, 2026 16:55 UTC |
Caveney Brian JEVP, Pres of ED, CMO & CSO
|
GrantCommon Stock | 9,304 | $0.00 | $0.00 |
DisclosureSEC source: 0000920148-26-000123 · form4.xml · nonDerivative · entry 1 Caveney Brian J · CIK 0001717915 · EVP, Pres of ED, CMO & CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,410.9234 F1 · kind: Shares acquired on March 26, 2026, pursuant to a performance award granted on February 7, 2023, relating to performance during the three-year period ended December 31, 2025. Read SEC document |
| March 26, 2026 Filed Mar 30, 2026 16:54 UTC |
Wilkinson Peter JSVP, Chief Accounting Officer
|
Tax withholdingCommon Stock | 755 | $268.38 | $202,626.90 |
DisclosureSEC source: 0000920148-26-000122 · form4.xml · nonDerivative · entry 2 Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,485.2194 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| March 26, 2026 Filed Mar 30, 2026 16:54 UTC |
Wilkinson Peter JSVP, Chief Accounting Officer
|
GrantCommon Stock | 2,388 | $0.00 | $0.00 |
DisclosureSEC source: 0000920148-26-000122 · form4.xml · nonDerivative · entry 1 Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,240.2194 F1 · kind: Shares acquired on March 26, 2026, pursuant to a performance award granted on February 7, 2023, relating to performance during the three-year period ended December 31, 2025. Read SEC document |
| March 26, 2026 Filed Mar 30, 2026 16:52 UTC |
Vaughn Bryan TEVP, Diagnostics
|
Tax withholdingCommon Stock | 451 | $268.38 | $121,039.38 |
DisclosureSEC source: 0000920148-26-000121 · form4.xml · nonDerivative · entry 2 Vaughn Bryan T · CIK 0002103999 · EVP, Diagnostics 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,745.5702 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| March 26, 2026 Filed Mar 30, 2026 16:52 UTC |
Vaughn Bryan TEVP, Diagnostics
|
GrantCommon Stock | 1,584 | $0.00 | $0.00 |
DisclosureSEC source: 0000920148-26-000121 · form4.xml · nonDerivative · entry 1 Vaughn Bryan T · CIK 0002103999 · EVP, Diagnostics 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,196.5702 F1 · kind: Shares acquired on March 26, 2026, pursuant to a performance award granted on February 7, 2023, relating to performance during the three-year period ended December 31, 2025. Read SEC document |
| March 26, 2026 Filed Mar 30, 2026 16:47 UTC |
Summy Amy B.EVP, Chief Marketing Officer
|
Tax withholdingCommon Stock | 1,836 | $268.38 | $492,745.68 |
DisclosureSEC source: 0000920148-26-000119 · form4.xml · nonDerivative · entry 2 Summy Amy B. · CIK 0001805303 · EVP, Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,879.5 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| March 26, 2026 Filed Mar 30, 2026 16:47 UTC |
Summy Amy B.EVP, Chief Marketing Officer
|
GrantCommon Stock | 3,994 | $0.00 | $0.00 |
DisclosureSEC source: 0000920148-26-000119 · form4.xml · nonDerivative · entry 1 Summy Amy B. · CIK 0001805303 · EVP, Chief Marketing Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,715.5 F1 · kind: Shares acquired on March 26, 2026, pursuant to a performance award granted on February 7, 2023, relating to performance during the three-year period ended December 31, 2025. Read SEC document |
| March 26, 2026 Filed Mar 30, 2026 16:49 UTC |
van der Vaart Sandra DEVP, Corporate Affairs
|
Tax withholdingCommon Stock | 2,722 | $268.38 | $730,530.36 |
DisclosureSEC source: 0000920148-26-000120 · form4.xml · nonDerivative · entry 2 van der Vaart Sandra D · CIK 0001537208 · EVP, Corporate Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,238.9467 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| March 26, 2026 Filed Mar 30, 2026 16:49 UTC |
van der Vaart Sandra DEVP, Corporate Affairs
|
GrantCommon Stock | 6,382 | $0.00 | $0.00 |
DisclosureSEC source: 0000920148-26-000120 · form4.xml · nonDerivative · entry 1 van der Vaart Sandra D · CIK 0001537208 · EVP, Corporate Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,960.9467 F1 · kind: Shares acquired on March 26, 2026, pursuant to a performance award granted on February 7, 2023, relating to performance during the three-year period ended December 31, 2025. Read SEC document |
| March 26, 2026 Filed Mar 30, 2026 16:46 UTC |
Oyegunwa AkinboladeEVP, CIO & CTO
|
Tax withholdingCommon Stock | 382 | $268.38 | $102,521.16 |
DisclosureSEC source: 0000920148-26-000118 · form4.xml · nonDerivative · entry 2 Oyegunwa Akinbolade · CIK 0002042869 · EVP, CIO & CTO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,064.253 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| March 26, 2026 Filed Mar 30, 2026 16:46 UTC |
Oyegunwa AkinboladeEVP, CIO & CTO
|
GrantCommon Stock | 1,340 | $0.00 | $0.00 |
DisclosureSEC source: 0000920148-26-000118 · form4.xml · nonDerivative · entry 1 Oyegunwa Akinbolade · CIK 0002042869 · EVP, CIO & CTO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,446.253 F1 · kind: Shares acquired on March 26, 2026, pursuant to a performance award granted on February 7, 2023, relating to performance during the three-year period ended December 31, 2025. Read SEC document |
| March 26, 2026 Filed Mar 30, 2026 16:42 UTC |
Bailey Megan D.EVP, Pres, Central Labs & Intl
|
Tax withholdingCommon Stock | 481 | $268.38 | $129,090.78 |
DisclosureSEC source: 0000920148-26-000115 · form4.xml · nonDerivative · entry 2 Bailey Megan D. · CIK 0001975682 · EVP, Pres, Central Labs & Intl 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,851 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| March 26, 2026 Filed Mar 30, 2026 16:42 UTC |
Bailey Megan D.EVP, Pres, Central Labs & Intl
|
GrantCommon Stock | 1,184 | $0.00 | $0.00 |
DisclosureSEC source: 0000920148-26-000115 · form4.xml · nonDerivative · entry 1 Bailey Megan D. · CIK 0001975682 · EVP, Pres, Central Labs & Intl 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,332 F1 · kind: Shares acquired on March 26, 2026, pursuant to a performance award granted on February 7, 2023, relating to performance during the three-year period ended December 31, 2025. Read SEC document |
| March 26, 2026 Filed Mar 30, 2026 16:44 UTC |
Meltzer Jonathan CEVP, Operations
|
Tax withholdingCommon Stock | 711 | $268.38 | $190,818.18 |
DisclosureSEC source: 0000920148-26-000117 · form4.xml · nonDerivative · entry 2 Meltzer Jonathan C · CIK 0002103998 · EVP, Operations 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,459.3256 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| March 26, 2026 Filed Mar 30, 2026 16:44 UTC |
Meltzer Jonathan CEVP, Operations
|
GrantCommon Stock | 2,388 | $0.00 | $0.00 |
DisclosureSEC source: 0000920148-26-000117 · form4.xml · nonDerivative · entry 1 Meltzer Jonathan C · CIK 0002103998 · EVP, Operations 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,170.3256 F1 · kind: Shares acquired on March 26, 2026, pursuant to a performance award granted on February 7, 2023, relating to performance during the three-year period ended December 31, 2025. Read SEC document |
| March 26, 2026 Filed Mar 30, 2026 16:43 UTC |
Kyle Kathryn WEVP, Chief Legal Officer
|
Tax withholdingCommon Stock | 451 | $268.38 | $121,039.38 |
DisclosureSEC source: 0000920148-26-000116 · form4.xml · nonDerivative · entry 2 Kyle Kathryn W · CIK 0002103996 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,575.4574 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.